Ameriprise
JUNO

Ameriprise’s Juno Therapeutics, Inc. JUNO Stock Holding History

Ameriprise’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-184,194
Closed -$8.43M – 3773
2017
Q4 		$8.43M Sell
184,194
-32,548
-15% -$1.62M ﹤0.01% 1739
2017
Q3 		$9.72M Sell
216,742
-157,868
-42% -$5.38M ﹤0.01% 1606
2017
Q2 		$11.2M Sell
374,610
-96,131
-20% -$2.37M 0.01% 1452
2017
Q1 		$10.4M Buy
470,741
+111,746
+31% +$2.4M 0.01% 1483
2016
Q4 		$6.77M Buy
+358,995
New +$8.78M ﹤0.01% 1805
2016
Q3 		– Sell
-383,023
Closed -$14.7M – 3879
2016
Q2 		$14.7M Sell
383,023
-119,191
-24% -$4.95M 0.01% 1102
2016
Q1 		$19.1M Buy
+502,214
New +$17.5M 0.01% 922
2015
Q4 		– Sell
-105,680
Closed -$4.3M – 3974
2015
Q3 		$4.3M Sell
105,680
-2,787
-3% -$122K ﹤0.01% 2115
2015
Q2 		$5.78M Sell
108,467
-41,568
-28% -$2.21M ﹤0.01% 2044
2015
Q1 		$9.1M Sell
150,035
-549,966
-79% -$26.7M 0.01% 1630
2014
Q4 		$36.5M Buy
+700,001
New +$31.3M 0.02% 655

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Ameriprise's JUNO Position: Q1 2018 in Review

Ameriprise sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 184,194 shares — an estimated $8.43M sold.

Ameriprise first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $36.5M in Q4 2014. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Ameriprise reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Ameriprise sold 184,194 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $8.43M.
  • Ameriprise first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Ameriprise's Juno Therapeutics, Inc. position peaked at $36.5M in Q4 2014.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Ameriprise's 13F filing for Q1 2018, filed 15 May 2018.